Phase 1 N=20 Characteristics of Glargine in Type 2 Diabetics
Type 2 Diabetes
Primary: Maximum Glucose Infusion Rate — 0.3; 2.6; 5.5; 6.8 umol/kg/min — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=356 New Moves - Obesity Prevention Among Adolescent Girls
Obesity
Primary: Percent Body Fat — 37.2; 37.7 % body fat (DXA)
Phase 1 N=34 Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone
Hepatitis C
Primary: R-methadone: Geometric Mean Steady-state AUC0-24 on Day 1 and on Day 9. — 6990; 5920 [ng*h/mL] — p=0.1638
Phase 3 N=131 Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial
Hepatitis C
Primary: Number of Patients With Investigator Defined Drug-related Adverse Events — 43; 43; 44 participants
Phase 1 N=29 Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers
Healthy
Primary: Group A - Efavirenz: Cmax — 771.0; 809.0 nmol/L
Phase 1 N=25 Pharmacokinetics of Faldaprevir of Soft Capsule
Healthy
Primary: Cmax,ss (After Multiple Dosing) — 3270; 14200 ng/mL
Phase 1 N=16 Drug-drug Interaction of BI 201335 and Microgynon
Hepatitis C, Chronic
Primary: AUCt,ss of Ethinylestradiol — 1010; 1450 pg*h/mL
Phase 1 N=25 Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir
Healthy
Primary: AUC( Tau,ss) — 4070; 11100 ng*h/mL — p=0.9999
N/A N=26 Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods
Accuracy of Tissue Diagnosis · Bile Duct Stricture · Pancreatic Duct Stricture
Primary: Percentage of Participants With Accurate Diagnoses of Cancer — 38.5; 53.9; 84.6 percentage of accurate diagnoses
Phase 1 N=51 Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin
Healthy
Primary: AUCτ,ss (Itraconazole Part) — 29900; 59500 ng*h/mL
N/A N=127 Senofilcon A Investigational Manufacturing Process
Visual Acuity · Comfort · Overall Vision
Primary: Subjective Overall Comfort (Using CLUE ) — 63.3; 65.0 units on a scale
Phase 2 N=20 Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
Kidney Transplantation
Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection
N/A N=80 Inhalation Intervention for Nausea in the Emergency Department
Nausea · Vomiting
Primary: Nausea Verbal Numerical Rating Scale (0-10) at 10 Minutes Post Intervention — 3; 6 VNRS
N/A N=27 A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)
COPD
Primary: Induced Sputum Proline-glycine-proline (PGP) Levels at Baseline — 0.74; 0.64 ng/ml
Phase 1 N=14 Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers
HIV Infections
Primary: AUCτ,ss of Darunavir — 57200; 66000 ng*h/mL